38 results about "Right ventricular hypertrophy" patented technology

The invention discloses annexin A2 (ANXA2) and application of an inhibitor thereof in diagnosis, treatment and / or prevention of pulmonary arterial hypertension. In particular discloses application of an ANXA2 inhibitor (including siRNA for silencing an ANXA2 gene, an ANXA2 antibody and a phosphorylation inhibitor) in preparation of a product for preventing and / or treating pulmonary arterial hypertension. Experiments prove that the ANXA2 inhibitor can significantly inhibit proliferation and migration of pulmonary artery smooth muscle cells, and significantly improve pulmonary arterial hypertension, pulmonary artery vascular remodeling and right ventricular hypertrophy. The ANXA2 or the Thr208 phosphorylation site of the ANXA2 protein can be used for diagnosis or auxiliary diagnosis of pulmonary arterial hypertension, or used for screening drugs for pulmonary arterial hypertension and developing new diagnosis and treatment methods and drugs. The therapeutic target and the ANXA2 inhibitor developed by the invention have wide clinical application value in the fields of diagnosis, prevention and treatment of pulmonary arterial hypertension.

The invention discloses an application of a benzotriazolyl piperazine compound or a salt thereof in preparation of a medicine for treating pulmonary arterial hypertension, and belongs to a new application of the benzotriazolyl piperazine compound. 3-[4-[4-(1H-benzotriazole-1-yl) butyl] piperazine-1-yl] benzisothiazole hydrochloride (PH-001) is subjected to an in-vivo animal experiment; mainly based on pharmacological experiments in a rat pulmonary arterial hypertension model induced by monocrotaline, it is found that the right ventricular systolic pressure (RVSP), the right ventricular hypertrophy index (RVHI) and the pulmonary arterial wall thickness (PAWT) of a rat are all remarkably reduced after intervention of a test sample PH-001, and the technical scheme opens up a new way for clinical application in the field of pulmonary arterial hypertension treatment. Therefore, PH symptoms and disease course development are effectively relieved, a theoretical basis is provided for clinical development, and the traditional Chinese medicine composition is expected to become a new effective treatment strategy.

The invention belongs to the technical field of medicines, and discloses an application of a small molecule compound in preparation of a product for preventing and / or treating pulmonary arterial hypertension and complications thereof. The small molecule compound is 8-[[4-(cyclopropanecarbonyl) piperazine-1-yl] methyl]-1, 3-dimethyl-7-(3-methylbutyl) purine-2, 6-diketone, and the structural formula is as shown in a formula (I): # imgabs0. The small molecule compound and pharmaceutically acceptable salts thereof have a remarkable treatment effect on pulmonary arterial hypertension and complications thereof, and can be used for treating pulmonary arterial hypertension and complications thereof. The effects of preventing and / or treating the pulmonary arterial hypertension include the reduction of right heart hypertrophy, the reduction of right ventricular systolic pressure, right heart enlargement, right heart dysfunction, pulmonary vascular remodeling, pulmonary arterial intima thickness, increase of vascular myelization, pulmonary arterial smooth muscle cell proliferation and migration, the reduction of the right ventricular hypertrophy, the reduction of the right ventricular hypertrophy, the reduction of the right ventricular hypertrophy and the reduction of the right ventricular hypertrophy. The pulmonary arterial intima thickness and the vascular myelization level are improved, pulmonary vascular remodeling is reversed, and pulmonary artery smooth muscle cell proliferation and migration are inhibited.

The present invention discloses the application of burdock root polysaccharide in the preparation of a medicament for treating pulmonary hypertension, belonging to the field of pharmaceutical technology. The present invention prepares a medicament for treating pulmonary hypertension with burdock root polysaccharide as the sole active ingredient. The medicament comprises an effective amount of burdock root polysaccharide and pharmaceutically acceptable excipients. Experimental results show that burdock root polysaccharide significantly reduces the increase in pulmonary artery pressure induced by monocrotaline in rats, significantly inhibits the increase in right ventricular hypertrophy index, significantly alleviates pulmonary artery endothelial injury, medial thickening, excessive proliferation of medial cells and infiltration of inflammatory cells in rats with pulmonary hypertension, significantly alleviates the degree of pulmonary artery vascular muscleization in rats with pulmonary hypertension, has the effects of reducing pulmonary artery vascular remodeling and lowering pulmonary artery pressure, and has a significant therapeutic effect on pulmonary hypertension and right ventricular hypertrophy in rats, and can be applied to the preparation of a medicament for treating pulmonary hypertension.

The invention relates to an application of a THBS4 inhibitor in preparation of a medicine for preventing and / or treating pulmonary arterial hypertension. Three pulmonary arterial hypertension rat models (a hypoxia induction model, a hypoxia combined SUGEN induction model and a monocrotaline induction model) are constructed, the expression change of THBS4 is verified through qRT-PCR and western blot, and the correlation between the expression level of THBS4 and pulmonary arterial hypertension is verified in combination with in-vitro cell experiments and in-vivo intervention. Results show that THBS4 is remarkably up-regulated in pulmonary arteries of the three models, the expression level of THBS4 is positively correlated with the severity of diseases, and THBS4 is an important regulatory factor for promoting vascular remodeling in pulmonary arterial hypertension. In vivo, by knocking down THBS4, pulmonary vascular remodeling and right ventricular hypertrophy are remarkably relieved, and it is prompted that THBS4 inhibitors show good application prospects in the aspect of preventing and / or treating pulmonary arterial hypertension.

The invention relates to the technical field of biological medicines, in particular to a pharmaceutical composition and application thereof in preparation of a medicine for treating the heart-lung qi deficiency type pulmonary heart disease. The pharmaceutical composition consists of 21-27 parts of astragalus membranaceus, 13-17 parts of semen lepidii, 7-10 parts of cassia twig, 21-27 parts of ligusticum wallichii, 7-10 parts of rhizoma alismatis, 5-7 parts of platycodon grandiflorum and 2-4 parts of Chinese dates. Compared with the prior art, the cassia twig is adopted to replace fructus psoraleae in an original formula, and meanwhile, the medicinal material specifications of the fried semen descurainiae, the raw ligusticum wallichii and the salted rhizoma alismatis are preferably selected. The invention also provides three preparation methods of the pharmaceutical composition, namely a water extraction and alcohol precipitation method, an alcohol extraction and water extraction combined method and a crushing and mixing method. Experimental results show that the pharmaceutical composition has remarkable effects on improving heart functions, lung functions, blood-gas indexes, right ventricular hypertrophy and the like of pulmonary heart disease model animals, meanwhile, the hepatotoxicity risk of fructus psoraleae is avoided, and the pharmaceutical composition has a good clinical application prospect.

In some aspects, the disclosure relates to GDF / BMP antagonists and methods of using GDF3 / BMP antagonists to treat, prevent, or reduce the progression rate and / or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and / or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF / BMP antagonist to treat, prevent, or reduce the progression rate and / or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF / BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

The application relates to a method for constructing a rat model of chronic obstructive pulmonary disease (COPD) related pulmonary arterial hypertension and application thereof, and belongs to the technical field of animal disease model construction. The method selects 6-8-week-old, 220+ / -10g healthy male SD rats, and all the rats are adaptively fed in a standard SPF level animal room for 7 days; then the rats are divided into a Con group and a COPD-PH group; the rats in the COPD-PH group are given 1mg / mL lipopolysaccharide by airway instillation on the first day and the 14th day; the rats are placed in a self-made whole-body inhalation smoking box for 1h every day from the 2nd day to the 13th day and from the 15th day to the 30th day; the rats enter a low-oxygen box for 8h every day during the light period from the 2nd day to the 13th day and from the 15th day to the 30th day; the rat model can simultaneously reproduce the characteristics of COPD and typical changes of pulmonary arterial hypertension, the right ventricular systolic pressure can be stably increased to 40-50mmHg, the right ventricular hypertrophy index can reach 0.40-0.50, the pulmonary vascular remodeling and inflammation are significant, and various indexes are stable and good in repeatability.

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.

In some aspects, the invention teaches pharmaceutical compositions comprising a TGF-beta ligand trapping agent, and methods of using the TGF-beta ligand trapping agent to treat, prevent, or reduce the rate of progression of pulmonary hypertension (PH). The invention also provides methods of using the TGF-beta ligand trapping agents to treat, prevent, or reduce the rate of progression of a variety of disorders, the conditions include, but are not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using the TGF-beta ligand trapping agent to reduce right ventricular systolic pressure in a subject.

The present invention provides stable, pure and potent compositions optimized for administration to neonates and / or preterm infants, and use of the same in methods for treating intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD), and / or chronic lung disease of prematurity (CLD), comprising administering to a subject in need of treatment a pharmaceutical composition comprising insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3), and a polysorbate 20 surfactant at high effective doses in low volumes in an infant resulting high serum IGF-1 exposure and treatment of IVH, BPD and / or CLD. In some aspects, provided herein are methods for manufacturing the compositions comprising a single-use bag, wherein the compositions have improved stability, reduced oxidation and increased potency. In some aspects, the methods provided result in reduced incidence of symptoms and features of intraventricular hemorrhage, bronchopulmonary dysplasia, right ventricular hypertrophy (RVH), pulmonary hypertension (PH), necrotizing enterocolitis, or chronic lung disease of prematurity.

The present invention belongs to the field of pulmonary vascular disease treatment, and specifically discloses a TGF-β receptor inhibitor for the treatment of pulmonary hypertension. In the rat pulmonary hypertension model induced by monocrotaline (MCT), after using the preparation, the right ventricular systolic pressure (RVSP), right ventricular hypertrophy (Fulton index), pulmonary vascular resistance and vascular wall thickness of the rat can be reversed and reduced, and the survival rate of monocrotaline (MCT)-induced pulmonary hypertension rats can be prolonged. Compared with the modeling group, the expression of IL-17, IL-6 and GM-CSF inflammatory factors in the lung tissue of the preparation-treated group was significantly reduced, and the expression of extracellular matrix-related genes CTGF, Fn1 and Col1α1 also decreased. The preparation can significantly alleviate the pulmonary hypertension in rats induced by monocrotaline (MCT), showing good therapeutic effect and application prospects.

The invention discloses application of ellagic acid to prevention of heart injury caused by long-term diving. A medicine for preventing heart injury caused by long-term diving is a medicine composition taking ellagic acid as a unique active ingredient or containing ellagic acid. According to the application of ellagic acid in prevention of heart injury caused by long-term phreatic water, animal in-vivo experiment results show that the morbidity of myocardial infarction of a long-term simulated phreatic water rat model is reduced to 23.8% from 44.8% through ellagic acid administration, the infarction area is remarkably reduced to 4.6 + / -3.3% from 14.9 + / -7.7%, the right ventricular hypertrophy index is reduced to 23.3 + / -6.5% from 34.5 + / -12.2%, and the curative effect is remarkable. The ellagic acid can effectively prevent rat heart injury caused by long-term diving. Therefore, ellagic acid has a good application prospect in prevention of heart injury caused by long-term diving.

The application discloses a traditional Chinese medicine composition for treating systemic lupus erythematosus (SLE) related pulmonary arterial hypertension and application, and relates to the technical field of traditional Chinese medicine, wherein the composition is prepared from pueraria, gotukola, salvia miltiorrhiza, chuanxiong, radix scrophulariae, poria cocos, wheat bran-fried atractylodes, dried tangerine or orange peel, prepared pinellia, baked licorice, immature bitter orange fruit and gotukola, and has the functions of activating blood circulation to remove blood stasis and clearing heat and resolving toxins, and is aimed at the pathogenesis of the heat-toxin blood stasis syndrome of SLE-PAH. The application further provides a preparation method of the composition. The composition can effectively reduce the pulmonary arterial pressure of a model animal, relieve right ventricular hypertrophy and pulmonary vascular remodeling, and improve the oxidation stress level in experiments. In combination with western medicine, the composition can significantly improve the exercise endurance of a patient, improve the pulmonary arterial systolic pressure and key serological indexes, and has a better curative effect than simple western medicine and good safety, thereby providing a safe and effective traditional Chinese medicine composition for treating SLE-PAH.

The invention discloses application of a compound in preparation of a medicine for preventing and / or treating pulmonary arterial hypertension. The structural formula of the compound in the formula I is # imgabs0. The compound in the formula I can improve the indexes of pulmonary systolic period acceleration time / pulmonary systolic period ejection time, right ventricular systolic pressure, right heart hypertrophy index, pulmonary vessel intima thickness, right ventricular anterior wall thickness, right ventricular inner diameter and the like of pulmonary arterial hypertension.

In some aspects, the disclosure relates to GDF / BMP antagonists and methods of using GDF / BMP antagonists to treat, prevent, or reduce the progression rate and / or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and / or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF / BMP antagonist to treat, prevent, or reduce the progression rate and / or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF / BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

The present disclosure belongs to the technical field of biomedicine, and specifically relates to use of a malic enzyme 1 (ME1) inhibitor in preparation of a drug for preventing and treating pulmonary hypertension (PH) and as a marker for detecting and / or treating the PH. Since a protein level and / or an enzymatic activity are significantly increased in a lung tissue, the ME1 can be used as a marker for detecting or treating the PH. Meanwhile, the ME1 inhibitor can ameliorate pulmonary vascular resistance (PVR) and right ventricular involvement / right heart failure in PH patients by reducing a right ventricular systolic pressure (RVSP) and a right ventricular hypertrophy index (RVHI). Therefore, the ME1 inhibitor can be used as a therapeutic target for treating the PH, thereby increasing a medical utility of the ME1 and the ME1 inhibitor.

The invention provides application of poncirin in preparation of a medicine for treating and / or preventing hypoxic pulmonary hypertension, and belongs to the technical field of medicines. According to the application of poncirin in preparation of the medicine for treating and / or preventing hypoxic pulmonary hypertension, the pulmonary hypertension, inflammatory factor release and pulmonary artery smooth muscle proliferation caused by hypoxia can be effectively improved, and the right ventricular pressure and the right ventricular hypertrophy index are remarkably reduced; effective drugs can be provided for treatment of diseases characterized by hypoxic pulmonary hypertension.

The invention belongs to the technical field of pulmonary heart disease treatment medicines, and particularly relates to a traditional Chinese medicine composition for treating qi deficiency and blood stasis water retention type pulmonary heart disease as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from radix astragali, radix salviae miltiorrhizae, radix paeoniae rubra, semen lepidii, cortex mori radicis and herba ephedrae. The traditional Chinese medicine composition can tonify qi and activate blood, release lung and relieve asthma, induce diuresis to alleviate edema, significantly improve oxyhemoglobin saturation and exercise tolerance, significantly reduce right ventricular systolic pressure and significantly inhibit right ventricular hypertrophy, so that the effect of treating the pulmonary heart disease is achieved by improving the cardiopulmonary function and pulmonary arterial hypertension; the traditional Chinese medicine composition can be used for preparing medicines for treating qi deficiency and blood stasis water retention type pulmonary heart disease, and can also be used for preparing medicines for improving oxyhemoglobin saturation and improving cardiopulmonary functions. Moreover, the traditional Chinese medicine composition is few in medicine flavor and low in clinical dosage, good medication compliance is easier to obtain, and the medication cost of a patient and the production cost for preparing a Chinese patent medicine by using the composition are reduced.

In some aspects, the disclosure relates to GDF / BMP antagonists and methods of using GDF / BMP antagonists to treat, prevent, or reduce the progression rate and / or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and / or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF / BMP antagonist to treat, prevent, or reduce the progression rate and / or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF / BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

The invention provides a traditional Chinese medicine composition for treating pulmonary arterial hypertension and application thereof, and belongs to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine composition for treating pulmonary arterial hypertension is prepared from the following components in parts by weight: 5-7 parts of herba ephedrae, 7-9 parts of semen armeniacae amarae, 20-24 parts of gypsum, 5-7 parts of liquorice root, 9-11 parts of radix salviae miltiorrhizae, 0.8-1.2 parts of leech and 2.5-3.5 parts of radix notoginseng. According to the treatment principle of freeing lung, relieving asthma and promoting blood circulation to remove blood stasis, ephedra, apricot kernel, gypsum and licorice granules with the effects of freeing lung, clearing heat and relieving asthma are used as monarch drugs, and salvia miltiorrhiza, leech and pseudo-ginseng with the effects of promoting blood circulation to remove blood stasis are used as ministerial drugs for compatibility; the prepared traditional Chinese medicine composition can reduce the length ratio of the right ventricle to the left ventricle plus ventricular septum and the length ratio of the right ventricle to the tibia, inhibit right ventricular hypertrophy, repair pulmonary vascular injury and improve the pulmonary ventilation function, the cardio-pulmonary function and pulmonary arterial hypertension.

The invention discloses application of aloe-emodin in preparation of a medicine for treating pulmonary arterial hypertension, and belongs to the technical field of biological medicine. The pulmonary arterial hypertension disease rat model is constructed through hypoxia (10%) induction. After aloe-emodin is injected into the intraperitoneal cavity, the conditions of fur, diet, activity, death and the like of the pulmonary arterial hypertension rat model are observed. Results show that the aloe-emodin (as shown in the formula I) has the effects of remarkably improving pulmonary vascular remodeling of animals with pulmonary hypertension, relieving right ventricular hypertrophy and right heart failure, improving the life quality of the animals with pulmonary hypertension (improving feeding and water inflow) and increasing the survival rate of the animals with pulmonary hypertension. The invention provides a new technical means for preventing and treating pulmonary arterial hypertension diseases. # imgabs0 #

The invention discloses an application of beta-aescin in prevention of heart injury caused by long-term diving. A medicine for preventing heart injury caused by long-term diving is a medicine composition which takes beta-aescin as a unique active ingredient or contains beta-aescin. According to the application of the beta-aescin to prevention of heart injury caused by long-term phreatic water, animal in-vivo experiment results show that the myocardial infarction area of a long-term simulated phreatic water rat model is remarkably reduced by 14.9 + / -7.7% to 6.5 + / -3.4% through administration of the beta-aescin, and although no statistical difference exists, the morbidity is reduced from 44.8% to 28.0%, so that the myocardial infarction area of the long-term simulated phreatic water rat model is obviously reduced by 14.9 + / -7.7% to 6.5 + / -3.4%. The right ventricular hypertrophy index is reduced from 34.5 + / -12.2% to 22.6 + / -5.6%, which indicates that the beta-aescin can effectively prevent rat heart injury caused by long-term diving. Therefore, the beta-aescin has a good application prospect in prevention of heart injury caused by long-term diving.

Methods of treating, preventing, or reducing the progression rate and / or severity of pulmonary hypertension (PH), particularly treating, preventing, or reducing the progression rate and / or severity of one or more PH-related complications, are provided.SOLUTION: In some aspects, the disclosure relates to GDF / BMP antagonists and methods of using GDF / BMP antagonists to treat, prevent, or reduce the progression rate and / or severity of PH. The disclosure also provides methods of using GDF / BMP antagonists to treat, prevent, or reduce the progression rate and / or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The present disclosure further provides methods of using a GDF / BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.SELECTED DRAWING: None

The present application proposes the use of new stemonaline in the preparation of drugs for the treatment of pulmonary hypertension, and relates to the technical field of medical drug development. The experiment of the present application confirms that the mouse pulmonary hypertension model using new stemonaline can significantly reduce the right ventricular hypertrophy and right ventricular systolic pressure of pulmonary hypertension, relieve the thickening of the middle layer of the pulmonary artery, and reduce the inflammatory response of lung tissue, and the weight of the mice has not changed compared with the control group. While having a good healing effect, no side effects have been found, which reflects that new stemonaline can be used as a safe and effective drug for the targeted treatment of inflammation and related symptoms caused by pulmonary hypertension.

The application provides use of a trisaccharide compound with a core structure of GlcN(1→4)IdoA(1→4)GlcNS in preparation of a drug for treating or preventing pulmonary arterial hypertension, which can effectively improve right ventricular hypertrophy, right ventricular function damage and hemodynamic parameters of an animal model of the pulmonary arterial hypertension, delay or improve excessive proliferation of arterial endothelial cells and smooth muscle cells in the pulmonary arterial hypertension, treat vascular remodeling and vascular muscularization of a pulmonary arterial hypertension patient, and has a good protective effect on a heart in the pulmonary arterial hypertension.

The present invention provides stable, pure and potent compositions optimized for administration to neonates and / or preterm infants, and use of the same in methods for treating intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD), and / or chronic lung disease of prematurity (CLD), comprising administering to a subject in need of treatment a pharmaceutical composition comprising insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3), and a polysorbate 20 surfactant at high effective doses in low volumes in an infant resulting high serum IGF-1 exposure and treatment of IVH, BPD and / or CLD. In some aspects, provided herein are methods for manufacturing the compositions comprising a single-use bag, wherein the compositions have improved stability, reduced oxidation and increased potency. In some aspects, the methods provided result in reduced incidence of symptoms and features of intraventricular hemorrhage, bronchopulmonary dysplasia, right ventricular hypertrophy (RVH), pulmonary hypertension (PH), necrotizing enterocolitis, or chronic lung disease of prematurity.

The invention belongs to the technical field of pulmonary arterial hypertension treatment medicines, and particularly relates to a composition for treating pulmonary arterial hypertension and application thereof. The composition comprises the following raw materials: pachymic acid B, cinnamic acid, atractylenolide I and glycyrrhizic acid. Experiments prove that for pulmonary arterial hypertension rats, the composition can obviously reverse decrease of the PAT / PET ratio, obviously relieve increase of right ventricular systolic pressure and average pulmonary arterial pressure, obviously relieve right ventricular hypertrophy index and obviously relieve PA myelization and pulmonary fibrosis of the pulmonary arterial hypertension rats. Therefore, the composition can be used for preparing medicines for treating pulmonary arterial hypertension.

A use of a trisaccharide compound having a core structure of GlcN(1→4)IdoA(1→4)GlcNS in the preparation of a drug for treating or preventing pulmonary hypertension. The drug can effectively alleviate right ventricular hypertrophy and right ventricular dysfunction and optimize hemodynamic parameters in an animal model of pulmonary hypertension, slow down or ameliorate excessive proliferation of arterial endothelial cells and smooth muscle cells in pulmonary hypertension, treat vascular remodeling and vascular muscularization in patients with pulmonary hypertension, and has a good protective effect on a heart in pulmonary hypertension.

The application provides a traditional Chinese medicine composition for treating pulmonary arterial hypertension and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is composed of ginseng, astragalus, cassia bark, prepared licorice, prepared rehmannia, angelica, white peony root, chuanxiong, persicae semen and safflower. The preparation method is as follows: water is added to decoct and extract to obtain a traditional Chinese medicine extract; the traditional Chinese medicine extract can be further concentrated into a clear paste, and excipients are added to prepare other dosage forms. Animal experiments show that the traditional Chinese medicine composition can significantly reduce the pulmonary arterial pressure of a hypoxic pulmonary arterial hypertension model rat, reduce the right ventricular hypertrophy index, reduce the wall thickness percentage and area percentage of pulmonary arterioles, increase the lumen area percentage of pulmonary arterioles, and effectively improve pulmonary vascular remodeling; clinical cases show that the traditional Chinese medicine composition can significantly improve the symptoms of pulmonary arterial hypertension and heart failure. The traditional Chinese medicine composition has the effects of tonifying qi, activating blood, removing blood stasis and dredging collaterals, can be used for preventing and / or treating pulmonary arterial hypertension, and has good safety.